Jennison Associates’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,127,474
| Closed | -$181M | – | 731 |
|
|
2020
Q3 | $181M | Sell |
2,127,474
-979,766
| -32% | -$49.5M | 0.15% | 65 |
|
|
2020
Q2 | $110M | Sell |
3,107,240
-1,914,054
| -38% | -$56M | 0.1% | 84 |
|
|
2020
Q1 | $67.7M | Buy |
5,021,294
+1,997,717
| +66% | +$33.6M | 0.08% | 104 |
|
|
2019
Q4 | $64M | Buy |
3,023,577
+271,637
| +10% | +$4.79M | 0.06% | 166 |
|
|
2019
Q3 | $36.5M | Sell |
2,751,940
-257,298
| -9% | -$3.78M | 0.04% | 234 |
|
|
2019
Q2 | $41.7M | Sell |
3,009,238
-32,179
| -1% | -$484K | 0.04% | 236 |
|
|
2019
Q1 | $58.4M | Buy |
3,041,417
+570,016
| +23% | +$9.19M | 0.06% | 197 |
|
|
2018
Q4 | $35.3M | Buy |
2,471,401
+309,886
| +14% | +$6.15M | 0.04% | 259 |
|
|
2018
Q3 | $45M | Buy |
2,161,515
+15,952
| +0.7% | +$378K | 0.04% | 265 |
|
|
2018
Q2 | $50.8M | Buy |
2,145,563
+35,186
| +2% | +$707K | 0.05% | 259 |
|
|
2018
Q1 | $30.8M | Buy |
2,110,377
+279,463
| +15% | +$4.57M | 0.03% | 331 |
|
|
2017
Q4 | $29.6M | Buy |
1,830,914
+19,195
| +1% | +$227K | 0.03% | 337 |
|
|
2017
Q3 | $25.3M | Buy |
1,811,719
+726,723
| +67% | +$7.24M | 0.03% | 372 |
|
|
2017
Q2 | $9.58M | Buy |
+1,084,996
| New | +$7.62M | 0.01% | 482 |
|
Jennison Associates's IMMU Position: Q4 2020 in Review
Jennison Associates sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 2,127,474 shares — an estimated $181M sold.
Jennison Associates first reported a position in IMMU in Q2 2017 and held it in 14 quarters. The position peaked at $181M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Jennison Associates reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Jennison Associates sold 2,127,474 Immunomedics Inc shares in Q4 2020, an estimated $181M.
- Jennison Associates first reported a position in Immunomedics Inc in Q2 2017 and held it in 14 quarters.
- Jennison Associates's Immunomedics Inc position peaked at $181M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Jennison Associates's 13F filing for Q4 2020, filed 5 Feb 2021.